Array BioPharma Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   November 30, 2010

Array BioPharma Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Colorado 000-31979 84-1460811
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
3200 Walnut Street, Boulder, Colorado   80301
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (303) 381-6600

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On November 30, 2010, Array BioPharma Inc. issued a press release announcing that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.





Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 - Press release dated November 30, 2010 entitled "ARRAY BIOPHARMA ACHIEVES CLINICAL MILESTONE IN CELGENE COLLABORATION."





Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Array BioPharma Inc.
          
November 30, 2010   By:   R. Michael Carruthers
       
        Name: R. Michael Carruthers
        Title: Chief Financial Officer

Top of the Form

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press release dated November 30, 2010 entitled "ARRAY BIOPHARMA ACHIEVES CLINICAL MILESTONE IN CELGENE COLLABORATION."